Cempra to Report Second Quarter 2017 Financial Results
July 20 2017 - 4:05PM
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company
focused on developing differentiated anti-infectives for acute care
and community settings to meet critical medical needs in the
treatment of infectious diseases, today announced that it will
report second quarter 2017 financial results before U.S. financial
markets open on Wednesday, August 9, 2017. Cempra management will
host a webcast and conference call at 8:45 a.m. ET that day to
discuss the financial results and provide a corporate update.
The live call may be accessed by dialing
877-377-7553 for domestic callers and 253-237-1151 for
international callers and using conference ID # 48439667. A live
webcast of the call will be available online from the investor
relations section of the company website at www.cempra.com and will
be archived there for 30 days. A telephone replay of the call will
be available by dialing 855-859-2056 for domestic callers or
404-537-3406 for international callers and entering the conference
ID # 48439667.
About Cempra, Inc.
Cempra, Inc. is a clinical-stage pharmaceutical
company focused on developing differentiated anti-infectives for
acute care and community settings to meet critical medical needs in
the treatment of infectious diseases. Cempra's two lead product
candidates are currently in advanced clinical development.
Solithromycin has been evaluated in two phase 3 clinical trials for
community-acquired bacterial pneumonia (CABP). Cempra is currently
seeking approval for CABP for both intravenous and oral capsule
formulations from the U.S. Food and Drug Administration.
Solithromycin is licensed to strategic commercial partner Toyama
Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation,
for certain exclusive rights in Japan. Cempra is contracted with
BARDA for the development of solithromycin for pediatric use and
has commenced enrollment in a global Phase 2/3 trial to evaluate
the safety and efficacy of solithromycin versus standard of care
antibiotics in children and adolescents from two months to 17 years
of age. Solithromycin is also in development for uncomplicated
urogenital urethritis caused by Neisseria gonorrhoeae or chlamydia.
Fusidic acid is Cempra's second product candidate, which has
completed a phase 3 trial comparing fusidic acid to linezolid in
patients with acute bacterial skin and skin structure infections
(ABSSSI). Cempra also has an ongoing exploratory study of fusidic
acid for chronic oral treatment of refractory infections in bones
and joints. Both products seek to address the need for new
treatments targeting drug-resistant bacterial infections in the
hospital and in the community. Cempra is also studying
solithromycin for ophthalmic conditions and has synthesized novel
macrolides for non-antibiotic uses such as the treatment of chronic
inflammatory diseases, endocrine diseases and gastric motility
disorders. Cempra was founded in 2006 and is headquartered in
Chapel Hill, N.C. For additional information about Cempra please
visit www.cempra.com.
Contact:
John Bluth
Cempra, Inc.
+1 984 209 4534
jbluth@cempra.com
Cempra (NASDAQ:CEMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cempra (NASDAQ:CEMP)
Historical Stock Chart
From Apr 2023 to Apr 2024